<DOC>
	<DOC>NCT01260857</DOC>
	<brief_summary>Aldazide 25 mg OD will be given to Filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.</brief_summary>
	<brief_title>Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension</brief_title>
	<detailed_description>Prospective, non-interventional non-probability sampling</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydroflumethiazide</mesh_term>
	<criteria>Patients &gt;/= 18 years old with Stage 1 or 2 hypertension not controlled by monotherapy or by a combination of antihypertensives without any diuretic yet. Pregnant or lactating women, with hypersensitivity to Aldazide, patients with resistant hypertension not controlled by a combination therapy with a diuretic in their regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Spirinolactone</keyword>
	<keyword>Hydroflumethiazide</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Filipinos</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Proteinuria</keyword>
</DOC>